The Akers–Agalloco Method - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Akers–Agalloco Method


Pharmaceutical Technology
Volume 29, Issue 11

Environmental technology risk


Table VII: Environmental technology.
Once the risk contributions from the components of an overall aseptic process have been determined, the authors recommend an overall adjustment according to the environmental technology providing the aseptic conditions. If aseptic compounding is a substantial part of the process, and is not performed using the same technology, the environmental factor should be applied separately and then added. The authors have placed an arbitrary weighting on the various technologies throughout this article (see Table VII). As stated earlier, consistency in the evaluation of an aseptic process will be manifest in the overall risk assessment, regardless of the specific values chosen.

Conclusion

In the application of the present method, a glaring difference in risk analysis "score" is apparent between conventional staffed aseptic processing and advanced technologies. Manual processes fare even more poorly. The authors believe that the distinctions this method reveals among different aseptic technologies are real and accurately represent the risk of contamination. The reader may disagree with the numerical weighting factors selected, but the rationale for them is sound. It is possible to debate the present recommendations in a strictly numerical sense, but such a debate would result only in subtle changes and would not materially affect the objective assessment of the differences among the various practices evaluated. This method should not be used to determine what is acceptable or unacceptable in absolute terms, but should serve as a means of identifying opportunities for process improvement, regardless of the practices and technologies used. There may come a time when a system similar to this one can be used to define the acceptability of practices for products, but that time has not yet arrived. The authors also see potential for the application of this method in the selection of technologies to be used.

Perhaps even more important, the authors believe that the present risk analysis model can facilitate the determination of an appropriate level of validation and revalidation suitable to the technology used. Aseptic technologies that either mitigate the risk of human intervention or eliminate such activities entirely through automation or separative technologies are inherently safer than technologies that allow direct human intervention. It follows that the more reliant a technology is on human intervention, the more risky it must be. Logically then, such traditional tests as the media fill are far less likely to provide value in assessing the performance of advanced technologies. Thus, media-fill test frequency could be reduced, as could sample size, particularly in systems that allow direct real time control and evaluation of the environment and the process.

In fact, the authors propose that it is possible to draw a clear line of demarcation between "advanced" aseptic technologies and more conventional systems using risk analysis. For a technology to be considered advanced, there must be no direct human intervention at any time. For example, a RABS system would be considered advanced only if there were never direct human interventions through temporarily opened barriers. Similarly, a blow–fill–seal system would be considered advanced only if no containers were put at risk after an intervention and the fluid path were subjected to sterilization-in-place before the resumption of manufacturing. In the authors' view, firms that invest in technologies that have been demonstrated objectively to mitigate risk and in which key control parameters can be measured and controlled in real time should benefit from reduced validation, revalidation, and traditional microbiological-monitoring requirements. Imposing the same validation requirements for advanced technologies as for more risk-intensive alternatives not only provides no safety benefit, it does actual harm through implementation delays caused by excessive requirements.

This article may be considered a positive step in an effort to assess risk in aseptic processing. The authors believe that a broadened perspective of risk relative to aseptic processing increases awareness that risk can vary substantially in what are perceived by many to be equivalent—and thus equally acceptable—practices and technologies. The authors welcome constructive criticism of this effort in the hope that it will lead to a clearer definition of risk issues and evaluation approaches as they relate to aseptic processing.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here